Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Management of Nonmetastatic Castration-Resistant Prostate Cancer: Recent Advances and Future Direction.

Esther J, Maughan BL, Anderson N, Agarwal N, Hahn AW.

Curr Treat Options Oncol. 2019 Feb 11;20(2):14. doi: 10.1007/s11864-019-0611-z. Review.

PMID:
30741354
2.

Managing Nonmetastatic Castration-resistant Prostate Cancer.

Mateo J, Fizazi K, Gillessen S, Heidenreich A, Perez-Lopez R, Oyen WJG, Shore N, Smith M, Sweeney C, Tombal B, Tomlins SA, de Bono JS.

Eur Urol. 2019 Feb;75(2):285-293. doi: 10.1016/j.eururo.2018.07.035. Epub 2018 Aug 14. Review.

3.

Apalutamide in the treatment of castrate-resistant prostate cancer: evidence from clinical trials.

Koshkin VS, Small EJ.

Ther Adv Urol. 2018 Nov 11;10(12):445-454. doi: 10.1177/1756287218811450. eCollection 2018 Dec. Review.

4.

Therapy of Advanced Prostate Cancer: Targeting the Androgen Receptor Axis in Earlier Lines of Treatment.

Shah H, Vaishampayan U.

Target Oncol. 2018 Dec;13(6):679-689. doi: 10.1007/s11523-018-0611-0.

PMID:
30536163
5.

Phase 2 Study of the Safety and Antitumor Activity of Apalutamide (ARN-509), a Potent Androgen Receptor Antagonist, in the High-risk Nonmetastatic Castration-resistant Prostate Cancer Cohort.

Smith MR, Antonarakis ES, Ryan CJ, Berry WR, Shore ND, Liu G, Alumkal JJ, Higano CS, Chow Maneval E, Bandekar R, de Boer CJ, Yu MK, Rathkopf DE.

Eur Urol. 2016 Dec;70(6):963-970. doi: 10.1016/j.eururo.2016.04.023. Epub 2016 May 6.

6.

[Influence of modern diagnostic methods on the treatment of nonmetastatic castration-resistant prostate cancer].

Kretschmer A, Tilki D.

Urologe A. 2019 Mar 18. doi: 10.1007/s00120-019-0904-7. [Epub ahead of print] Review. German.

PMID:
30887058
7.

The Current Landscape of Treatment in Non-Metastatic Castration-Resistant Prostate Cancer.

El-Amm J, Aragon-Ching JB.

Clin Med Insights Oncol. 2019 Mar 7;13:1179554919833927. doi: 10.1177/1179554919833927. eCollection 2019. Review.

8.

Non-metastatic castration resistant prostate cancer: a review of current and emerging medical therapies.

Alpajaro SIR, Harris JAK, Evans CP.

Prostate Cancer Prostatic Dis. 2019 Mar;22(1):16-23. doi: 10.1038/s41391-018-0078-1. Epub 2018 Aug 16. Review.

PMID:
30115959
9.

Profile of apalutamide in the treatment of metastatic castration-resistant prostate cancer: evidence to date.

Chong JT, Oh WK, Liaw BC.

Onco Targets Ther. 2018 Apr 12;11:2141-2147. doi: 10.2147/OTT.S147168. eCollection 2018. Review.

10.

Effect of apalutamide on health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the SPARTAN randomised, placebo-controlled, phase 3 trial.

Saad F, Cella D, Basch E, Hadaschik BA, Mainwaring PN, Oudard S, Graff JN, McQuarrie K, Li S, Hudgens S, Lawson J, Lopez-Gitlitz A, Yu MK, Smith MR, Small EJ.

Lancet Oncol. 2018 Oct;19(10):1404-1416. doi: 10.1016/S1470-2045(18)30456-X. Epub 2018 Sep 10.

PMID:
30213449
11.

Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer.

Smith MR, Saad F, Chowdhury S, Oudard S, Hadaschik BA, Graff JN, Olmos D, Mainwaring PN, Lee JY, Uemura H, Lopez-Gitlitz A, Trudel GC, Espina BM, Shu Y, Park YC, Rackoff WR, Yu MK, Small EJ; SPARTAN Investigators.

N Engl J Med. 2018 Apr 12;378(15):1408-1418. doi: 10.1056/NEJMoa1715546. Epub 2018 Feb 8.

12.

Clinical Development of Darolutamide: A Novel Androgen Receptor Antagonist for the Treatment of Prostate Cancer.

Fizazi K, Smith MR, Tombal B.

Clin Genitourin Cancer. 2018 Oct;16(5):332-340. doi: 10.1016/j.clgc.2018.07.017. Epub 2018 Jul 24. Review.

13.

Androgen receptor mutations in patients with castration-resistant prostate cancer treated with apalutamide.

Rathkopf DE, Smith MR, Ryan CJ, Berry WR, Shore ND, Liu G, Higano CS, Alumkal JJ, Hauke R, Tutrone RF, Saleh M, Chow Maneval E, Thomas S, Ricci DS, Yu MK, de Boer CJ, Trinh A, Kheoh T, Bandekar R, Scher HI, Antonarakis ES.

Ann Oncol. 2017 Sep 1;28(9):2264-2271. doi: 10.1093/annonc/mdx283.

14.

Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer.

Hussain M, Fizazi K, Saad F, Rathenborg P, Shore N, Ferreira U, Ivashchenko P, Demirhan E, Modelska K, Phung, Krivoshik A, Sternberg CN.

N Engl J Med. 2018 Jun 28;378(26):2465-2474. doi: 10.1056/NEJMoa1800536.

15.

Management of nonmetastatic castration-resistant prostate cancer.

Traboulsi SL, Saad F.

Curr Opin Support Palliat Care. 2018 Sep;12(3):366-371. doi: 10.1097/SPC.0000000000000356.

PMID:
30015690
16.

Androgen Receptor Targeted Treatments of Prostate Cancer: 35 Years of Progress with Antiandrogens.

Crawford ED, Schellhammer PF, McLeod DG, Moul JW, Higano CS, Shore N, Denis L, Iversen P, Eisenberger MA, Labrie F.

J Urol. 2018 Nov;200(5):956-966. doi: 10.1016/j.juro.2018.04.083. Epub 2018 May 3. Review.

PMID:
29730201
17.

Moving Towards Precision Urologic Oncology: Targeting Enzalutamide-resistant Prostate Cancer and Mutated Forms of the Androgen Receptor Using the Novel Inhibitor Darolutamide (ODM-201).

Borgmann H, Lallous N, Ozistanbullu D, Beraldi E, Paul N, Dalal K, Fazli L, Haferkamp A, Lejeune P, Cherkasov A, Gleave ME.

Eur Urol. 2018 Jan;73(1):4-8. doi: 10.1016/j.eururo.2017.08.012. Epub 2017 Aug 26.

PMID:
28851578
18.

Darolutamide (ODM-201) for the treatment of prostate cancer.

Shore ND.

Expert Opin Pharmacother. 2017 Jun;18(9):945-952. doi: 10.1080/14656566.2017.1329820. Epub 2017 May 24. Review.

PMID:
28490267
19.

Non-metastatic castrate-resistant prostate cancer: a call for improved guidance on clinical management.

Rozet F, Roumeguère T, Spahn M, Beyersdorff D, Hammerer P.

World J Urol. 2016 Nov;34(11):1505-1513. Epub 2016 Mar 17. Review.

PMID:
26988552
20.

Enzalutamide Versus Bicalutamide in Castration-Resistant Prostate Cancer: The STRIVE Trial.

Penson DF, Armstrong AJ, Concepcion R, Agarwal N, Olsson C, Karsh L, Dunshee C, Wang F, Wu K, Krivoshik A, Phung D, Higano CS.

J Clin Oncol. 2016 Jun 20;34(18):2098-106. doi: 10.1200/JCO.2015.64.9285. Epub 2016 Jan 25.

PMID:
26811535

Supplemental Content

Support Center